title: Treatment options in relapsed or refractory Hodgkin disease patients: the mini-BEAM regimen does exist too.
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Canales
authors.forename: Alejandro
authors.initials: A
authors.lastname: Martin
authors.forename: Dolores
authors.initials: D
authors.lastname: Caballero
authors.forename: Fernando
authors.initials: F
authors.lastname: Hernandez-Navarro
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002330:Carmustine / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005047:Etoposide / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use; D012008:Recurrence; D016879:Salvage Therapy
chemical_list: D003561:Cytarabine; D005047:Etoposide; D008558:Melphalan; D002330:Carmustine